Lp-PLA2 appears to be associated with inflammation/immune activation, but also with anti-thrombotic effects. Lp-PLA2 may represent a valuable early biomarker of CVD risk in HIV infection before subclinical atherosclerosis can be detected. “
“People living with HIV infection

are at increased risk for developing cardiovascular disease (CVD). Safe and effective interventions for lowering CVD risk in HIV infection are high priorities. We conducted a prospective, randomized, controlled study to evaluate whether a yoga lifestyle intervention improves CVD risk factors, virological or immunological status, or quality of life (QOL) in HIV-infected adults relative to click here standard of care treatment in a matched control group. Sixty HIV-infected adults with mild–moderate CVD risk were assigned to 20 weeks of supervised yoga practice or standard of care treatment. Baseline and week 20 measures were: 2-h oral glucose tolerance test with insulin monitoring, body composition, fasting serum lipid/lipoprotein profile, resting blood pressures, CD4 T-cell PF-02341066 nmr count and plasma HIV RNA, and the Medical Outcomes Study Short Form (SF)-36 health-related QOL inventory. Resting systolic and diastolic blood pressures improved more (P=0.04) in the yoga group

(−5 ± 2 and −3 ± 1 mmHg, respectively) than in the standard of care group (+1 ± 2 and+2 ± 2 mmHg, respectively). However, there was no greater reduction in body weight, fat mass or proatherogenic lipids, or improvements in glucose tolerance or overall QOL after yoga. Immune and virological status was not adversely affected. Among traditional lifestyle modifications, yoga is a low-cost, simple to administer, nonpharmacological, popular behavioural intervention that can lower blood pressure in pre-hypertensive HIV-infected adults with mild–moderate CVD risk factors. Infection with HIV and treatment with combination antiretroviral therapy (cART) have been

associated with several metabolic and anthropomorphic alterations that increase cardiovascular disease (CVD) SB-3CT risk [1,2]. These alterations include insulin resistance, dyslipidaemia, visceral adiposity, subcutaneous lipoatrophy, and bone demineralization, and several are components of the cardiometabolic syndrome. cART has effectively reduced HIV-related morbidity and mortality, but HIV-infected people are living longer with significant CVD risk. HIV service providers are confronted with the challenge of effectively addressing CVD risk, and specifically identifying traditional or alternative/complementary therapies that may reduce CVD risk in HIV infection. People living with HIV, taking cART, and experiencing cardiometabolic syndromes often use alternative or complementary therapies to manage side-effects of HIV or cART [3–7].